EN DE
Watch Theragen Etex Co.Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Theragen Etex Co.Ltd (066700) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Theragen Etex Co.Ltd stock KRW 4,176, price KRW 2,025, upside +106.2%, quality 53 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7066700006

TE Theragen Etex Co.Ltd logo Some data Nov 15, 2026

Theragen Etex Co.Ltd

066700 · KQ

Cheap (52% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Follow free in the weekly email
Fair value 4,176 KRW · Strongly undervalued 
Low debt 
Generates free cash flow 
Ranks above peers (8/12) 
Even on cautious assumptions the value is 52% above the price (3,083 KRW). 
Quality 53/100 
Mixed Growth (revenue 5y +13.7 %/yr in KRW) 
Thin margins · 3.5% net margin (TTM) 
Some data 
Falling price (downtrend) 
Narrow moat 35/100 · thin data
⚠ Dilution
Watch Theragen Etex Co.Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

8,770 KRW 1,888 KRW Fair Value 4,176 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 1,888 KRW – 8,770 KRW · fair‑value band 3,083 KRW – 5,220 KRW · the 2,025 KRW price screens below the 4,176 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 15, 2026.

Follow Theragen Etex Co.Ltd in your weekly email

Every Wednesday you see whether Theragen Etex Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products.

Show moreShow less

It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others.

The company was formerly known as Theragen Co., Ltd. and changed its name to Theragen Etex Co.,Ltd. in July 2010. Theragen Etex Co.,Ltd. was founded in 1987 and is headquartered in Seoul, South Korea.

Stock analysis

Theragen Etex Co.Ltd (066700) currently trades at 2,025 KRW, while our model-based Fair Value estimate is 4,176 KRW, implying the stock looks roughly 52% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 5,611 KRW per share, and 23 of the 26 models we run sit above the 2,025 KRW price.

Bear case: the Asset-Based group reads lowest at 1,499 KRW, and 3 of the 26 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 3,083 KRW (bear) to 5,220 KRW (bull), the price of 2,025 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Theragen Etex Co.Ltd reported revenue of 272B KRW in FY2025 versus 167B KRW in FY2021, a compound +13.0%/yr. Reported net income was 10.6B KRW in FY2025.

Key figures

Market cap 74.3B KRW (≈ $55.8M) Micro · P/S ratio 0.39 · Dividend yield 0.1% · Net margin 3.5% · Return on equity −3,202% · Return on assets (EBIT) 3.6% (5-year average) · Operating margin 2.8% · Revenue (TTM) 189B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 106%, 066700 screens cheaper than that median.

Fair Value models

Bear 3,083 KRW Fair Value 4,176 KRW Bull 5,220 KRW
Price 2,025 KRW · Upside +106.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 2,888 KRW 4,042 KRW 5,690 KRW 80
Growth DCF 2,850 KRW 3,843 KRW 5,158 KRW 78
Owner Earnings 3,710 KRW 5,344 KRW 7,679 KRW 76
All 26 models by family
DCF Models
FCF DCF 2,888 KRW 4,042 KRW 5,690 KRW 80
Owner Earnings 3,710 KRW 5,344 KRW 7,679 KRW 76
5Y Revenue Exit 3,168 KRW 4,841 KRW 7,107 KRW 71
5Y EBITDA Exit 4,267 KRW 7,100 KRW 10,672 KRW 73
5Y P/E Exit 4,262 KRW 7,090 KRW 10,335 KRW 69
10Y Revenue Exit 2,948 KRW 4,339 KRW 6,450 KRW 65
10Y EBITDA Exit 3,630 KRW 5,743 KRW 8,978 KRW 66
10Y P/E Exit 3,628 KRW 5,737 KRW 8,739 KRW 62
Earnings-Based
Graham-Dodd 1,965 KRW 9,098 KRW 12,495 KRW 61
Lynch FV 2,413 KRW 3,447 KRW 4,481 KRW 58
PEG = 1.0 2,413 KRW 3,447 KRW 4,481 KRW 55
EPV 2,685 KRW 2,895 KRW 3,065 KRW 72
Dividend Discount
Gordon GGM 18.65 KRW 31.06 KRW 40.14 KRW 66
DDM Multi-Stage 18.65 KRW 29.54 KRW 33.43 KRW 65
Multiples
P/E Multiple 4,768 KRW 6,357 KRW 7,947 KRW 61
P/S Multiple 3,684 KRW 4,913 KRW 6,141 KRW 56
P/B Multiple 2,899 KRW 3,865 KRW 4,831 KRW 53
EV/EBIT 3,404 KRW 4,587 KRW 5,770 KRW 65
EV/EBITDA 4,631 KRW 6,224 KRW 7,816 KRW 66
EV/Revenue 2,388 KRW 3,474 KRW 4,559 KRW 52
Asset-Based
NCAV (Graham) 989.15 KRW 1,499 KRW 1,873 KRW 53
Growth DCF
Growth DCF 2,850 KRW 3,843 KRW 5,158 KRW 78
Rev-Margin DCF 3,168 KRW 4,800 KRW 6,904 KRW 71
Economic Profit
Residual Income 2,782 KRW 2,778 KRW 3,006 KRW 75
ROIC Compounder 2,685 KRW 2,895 KRW 3,065 KRW 71
Growth Earnings
Growth-Adj P/E 3,928 KRW 5,611 KRW 7,295 KRW 66

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 56
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 17
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +10.6% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.1%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−27.4% vs 13.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 4%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.6% a year for the price.

Watch 066700, get fair value alerts →

Compare Theragen Etex Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside +106.2% · Top 25%
Profitability
Return on assets 4.1% · Above median
Net margin (12 months) 3.5% · Below median
Operating margin (12 months) 2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 13.4% · Above median
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 0.53× · Cheaper than median
P/S (12 months) 0.39× · Cheapest 25%
Price / free cash flow (fiscal year) 12.9× · Pricier than median
EV/EBITDA 3.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 11
FUTURE (revenue growth)67 · sector 67
PAST (return on equity)0 · sector 24
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)3 · sector 27

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,300 KRW 47,019 KRW +144% vs 066700
DongKook Pharmaceutical Co 086450 24,400 KRW 28,372 KRW +16% vs 066700
ST Pharm Co 237690 70,200 KRW 61,182 KRW −13% vs 066700
Vivozon Pharmaceutical Co 082800 2,780 KRW 2,179 KRW −22% vs 066700
Oscotec Inc 039200 32,300 KRW 21,262 KRW −34% vs 066700
NatureCell Co 007390 21,450 KRW 11,176 KRW −48% vs 066700
Mezzion Pharma Co 140410 64,800 KRW 31,450 KRW −51% vs 066700
BINEX Co 053030 6,850 KRW 1,844 KRW −73% vs 066700
Caregen Co 214370 26,600 KRW 5,414 KRW −80% vs 066700
SHUKRAPHAR SHUKRAPHAR ₹82.23 ₹9.14 −89% vs 066700

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Theragen Etex Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Theragen Etex Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/066700

Frequently asked questions

Is Theragen Etex Co.Ltd (066700) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 4,176 KRW versus a price of 2,025 KRW, about +106% upside (undervalued).
What is the fair value of 066700?
Our model-based fair value for Theragen Etex Co.Ltd is 4,176 KRW (as of Nov 15, 2026), built from audited fundamentals. The current price: 2,025 KRW.
What is the quality score of 066700?
Theragen Etex Co.Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Theragen Etex Co.Ltd (066700)?
Our model-based price target is the fair value of 4,176 KRW (as of Nov 15, 2026) from 26 valuation models. Cautious scenario 3,083 KRW, optimistic scenario 5,220 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Theragen Etex Co.Ltd stock forecast for 2026?
Our models put fair value at 4,176 KRW, about +106% upside versus a price of 2,025 KRW (undervalued). Cautious scenario 3,083 KRW, optimistic scenario 5,220 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Theragen Etex Co.Ltd (066700)?
Theragen Etex Co.Ltd reported trailing-twelve-month revenue of about 189B KRW (latest available figure, as of Nov 15, 2026).
Does Theragen Etex Co.Ltd pay a dividend?
Theragen Etex Co.Ltd currently shows a dividend yield of 0.13% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Theragen Etex Co.Ltd (066700)?
Theragen Etex Co.Ltd has a dividend yield of 0.1%.
What growth is priced into Theragen Etex Co.Ltd (066700)?
For today's price to be fair in a discounted-cash-flow model, Theragen Etex Co.Ltd would have to grow free cash flow by 11.8 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 13.7 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 066700 use?
Our models discount Theragen Etex Co.Ltd at 12.6 %: a base by market capitalisation (micro), damped by beta 0.85, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Theragen Etex Co.Ltd that is +11.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Theragen Etex Co.Ltd (066700) delivered so far?
Over the past 5 years revenue at Theragen Etex Co.Ltd grew 13.7 % a year. The price currently implies free-cash-flow growth of +11.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Theragen Etex Co.Ltd (066700) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Theragen Etex Co.Ltd (+11.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Theragen Etex Co.Ltd (066700)?
The free-cash-flow yield on the price is 7.77 %: that much free cash flow Theragen Etex Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Theragen Etex Co.Ltd (066700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Theragen Etex Co.Ltd it is 4,176 KRW per share (as of Nov 15, 2026), against a price of 2,025 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Theragen Etex Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 066700 trades below its calculated fair value: price 2,025 KRW, fair value 4,176 KRW, a gap of about +106% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 066700?
No. The price is what the market pays today (2,025 KRW); the fair value is what the company's own numbers justify (4,176 KRW). For Theragen Etex Co.Ltd the two are 2,151 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Theragen Etex Co.Ltd worth?
The market values Theragen Etex Co.Ltd at about 74.3B KRW (market capitalisation, as of Nov 15, 2026). Per share that is 2,025 KRW; our models calculate a fair value of 4,176 KRW per share.
What do the bullish and bearish scenarios say about 066700?
Our models span a range for Theragen Etex Co.Ltd: cautious scenario 3,083 KRW, base 4,176 KRW, optimistic 5,220 KRW per share (as of Nov 15, 2026, price 2,025 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Theragen Etex Co.Ltd (066700)?
Balance-sheet figures for Theragen Etex Co.Ltd (as of Nov 15, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 066700 from its 52-week high?
Theragen Etex Co.Ltd trades at 2,025 KRW, about 39% below its 52-week high of 3,315 KRW and 7% above the low of 1,888 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 4,176 KRW is for.
Which stocks are comparable to Theragen Etex Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Theragen Etex Co.Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price 2,025 KRW, calculated fair value 4,176 KRW (+106%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 066700 calculated?
We run Theragen Etex Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4,176 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Theragen Etex Co.Ltd currently trades 52% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Theragen Etex Co.Ltd (066700)?
The closing price on Nov 18, 2026 was 2,025 KRW. Our model-based fair value is 4,176 KRW, about +106% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Theragen Etex Co.Ltd right now?
The price is below even our cautious bear case (3,083 KRW). The market is more pessimistic than our downside scenario. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Theragen Etex Co.Ltd

How large is the market capitalisation of Theragen Etex Co.Ltd (066700)?
The market capitalisation of Theragen Etex Co.Ltd is 74.3B KRW (≈ $55.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Theragen Etex Co.Ltd (066700)?
The price-to-sales ratio of Theragen Etex Co.Ltd is 0.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Theragen Etex Co.Ltd (066700)?
The dividend yield of Theragen Etex Co.Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Theragen Etex Co.Ltd (066700)?
The net margin of Theragen Etex Co.Ltd is 3.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Theragen Etex Co.Ltd (066700)?
The return on equity (ROE) of Theragen Etex Co.Ltd is −3,202% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Theragen Etex Co.Ltd (066700)?
On an EBIT basis the return on assets of Theragen Etex Co.Ltd is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Theragen Etex Co.Ltd (066700)?
The operating margin of Theragen Etex Co.Ltd is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Theragen Etex Co.Ltd (066700)?
Revenue at Theragen Etex Co.Ltd is growing 13.4% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Theragen Etex Co.Ltd (066700) carry?
The net debt of Theragen Etex Co.Ltd is 5.3B KRW (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Theragen Etex Co.Ltd in the live analysis

One click puts Theragen Etex Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.